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Abstract: Small molecule heterocycles bearing orthogonal 
functionality have the potential to deliver diverse structural motifs that 
aid the drug discovery effort. This work highlights how a readily 
assembled N-hydroxyethyl pyrazole trifluoroborate offers rapid 
access to architecturally distinct 5-6-6 and 5-7-6 fused tricyclic 
compounds. This chemistry is not only amenable to single compound 
synthesis, but also to high throughput experimentation. It enables 
easy access to diverse compound arrays with varying physchem and 
ADME profiles by fully automated library synthesis. The combination 
of the high throughput experimentation with rapid testing of the 
compounds in an integrated physchem and ADME profiling workflow 
allows accelerated design of novel lead compounds in drug discovery 
projects. 
Introduction 
Heteroaromatic scaffolds are prominent structural motifs in 
pharmaceutical agents, agrochemicals and functional materials; 
this aspect has motivated synthetic chemists to devise new 
strategies for their efficient and selective incorporation into a 
broad range of biologically active molecules. Boronic acid 
chemistry provides one of the most widely used approaches for 
the coupling of heteroaromatic systems because of the synthetic 
versatility of these compounds.[1] Several complementary 
strategies are available that enable rapid access to heterocyclic 
boronic acid derivatives, including borylation of C-X/C-H bonds,[2] 
cycloadditions[3] and cyclization[4] processes. In preceding 
publications, we have described the efficient synthesis of N-
substituted pyrazole-5-trifluoroborate salts[5] and thiophene-5-
trifluoroborates[6] from a common intermediate: an ynone 
trifluoroborate. We have demonstrated the compatibility of the 
trifluoroborate handle with condensation reactions, yielding 
heterocycles bearing the borate group readily installed. 
Pyrazoles are a remarkably prevalent moiety in drug 
discovery,[7] and we envisaged that our route to N-substituted 
pyrazole-5-trifluoroborate salts would allow easy access to novel 
types of fused tricyclic scaffolds with this privileged heterocycle at 
their core. Specifically, as shown in Scheme 1, condensation of 
hydroxyethyl hydrazide with the ynone would provide 
intermediate 1 that could be elaborated in a divergent manner to 
an oxazepane bridged tricycle 3, or a piperazine bridged tricycle 
5. We report herein the successful implementation of this strategy 
and their profiling with regard to physicochemical and eADME 
properties. 
 
Scheme 1. Divergent strategy to pyrazole-based tricycles. 
Results and Discussion 
We began our studies by undertaking the condensation of N-
ethanolhydrazine with phenylynone trifluoroborate 6. We were 
pleased to find that this cyclization proceeded smoothly, 
furnishing potassium 2-(3-phenyl-5-(trifluoroboranyl)-1H-pyrazol-
1-yl)ethan-1-ol 7 in excellent yield and regioselectivity (98%, 98:2; 
Scheme 2). Due to the significant difference in solubility of both 
regioisomers in acetone, the isolation of the desired major isomer 
in pure form was straightforward; this regioisomer was then used 
to generate two types of libraries, one leading to 5-7-6 fused 
tricycles, the other furnishing the 5-6-6 fused chemotype. Suzuki-
Miyaura cross-coupling reactions were performed using an 
automated library synthesis/purification system available at 
Sanofi R&D in Frankfurt, Germany. 
 
Scheme 2. Condensation of trifluoroborate 6 with N-ethanolhydrazine. 
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Synthesis of oxazepane bridged tricycles: For this first library, we 
had envisioned the introduction of an ortho-fluoride in the arene 
introduced during the Suzuki cross-coupling step, enabling a 
cyclization via nucleophilic aromatic substitution (Scheme 1, 2 → 
3). This approach complements the elegant synthesis of this class 
of tricycles by Virelli et al.[8] In the event, this two-step sequence 
worked well in general, and all compounds were characterized by 
1H NMR spectroscopy and LC-MS (with a small selection 
submitted for full characterization). These compounds were 
subsequently subjected to physchem and eADME profiling, and 
the results are summarized in Table 1. This approach allowed us 
to access diverse compounds with an attractive range of 
molecular weights and logD values spanning from 0 to 5. The 
generated scaffolds show limited solublity in water (pH 7.4) with 
only three candidates exhibiting a solubility >20 mg/mL, 
highlighting the importance of the substitution pattern for this 
parameter. Whereas the cell permeability (Caco-2 
measurements) was generally good with values >20x10-7 cm/s for 
four of the compounds, the metabolic lability of these compounds 
in human microsomes was generally high; only 3 compounds 
showed values below 40% (9a, 9b and 9h). Finally, all but 9d 
showed CYP Inhibition values with IC50 values >30.0 µM, which 
is not surprising given the presence of an unsubstituted pyridine 
moiety in this particular example.[9] 
Table 1. Physical and biological properties of oxazepane bridged tricycles.  
 
Product Mol. Wt. Caco-2[a] Metabolic lability[b] logD[c] CYP inhibition[d] Solubility[e] 
9a 306.3 63.9 20 -0.04 > 30.0 1632 
9b 340.4 53.6 -9 2.10 > 30.0 3 
9c 330.3 NoVal 45 4.39 > 30.0 3 
9d 263.3 NoVal NoVal 1.48 14.6 87 
9e 280.3 80.2 65 3.58 > 30.0 4 
9f 331.3 NoVal 46 4.08 > 30.0 3 
9g 307.3 NoVal 68 3.44 > 30.0 3 
9h 375.4 154.7 38 1.77 > 30.0 26 
[a] Caco-2; Mean; PTotal (A2B) (10-7 cm/s). [b] Metabolic lability in human microsomes; Total Metabolism (%), no CYP inhibitor added. [c] LogD (pH 7.4). [d] CYP 
inhibition, IC50 (INH) (M), Isoform: CYP3A4, Substrate: Midazolam. [e] Solubility (pH 7.4; mg/ml), Mean. NoVal: Insufficient sample to perform the assay in this 
case.   
 
The successful synthesis of compound 9a highlighted that 
carboxylic acids could be tolerated in the coupling-cyclization 
sequence. We recognized that this offered a platform to exploit 
this vector in amide bond forming reactions, and we therefore 
prepared a further library with a range of amines coupled with 
carboxylic acid 9i. The physchem and eADME profile of this new 
library is summarized in Table 2. 
 
Table 2. Physical and biological properties of tricycle amide library.  













10i 375.4 205.2 13 1.80 > 30.0 230 10xv 400.4 57.2 6 1.17 > 30.0 80 
10ii 361.5 189.1 31 2.69 > 30.0 29 10xvi 377.5 186.5 91 2.42 > 30.0 54 
10iii 396.5 149.3 43 2.24 > 30.0 < 3 10xvii 402.5 184.8 63 2.23 5.8 < 3 
10iv 532.5 80.9 22 1.11 > 30.0 > 939 10xviii 376.4 136.8 13 1.36 > 30.0 4 
10v 377.5 141.8 30 1.71 > 30.0 > 1325 10xix 587.6 82.7 70 1.96 > 30.0 11 
10vi 405.5 NoVal 93 2.64 > 30.0 < 3 10xx 417.5 210.7 90 2.32 > 30.0 > 1198 
10vii 375.4 NoVal 6 1.25 > 30.0 > 1332 10xxi 402.5 36.0 14 1.26 > 30.0 227 
10viii 528.5 14.2 8 1.07 > 30.0 > 946 10xxii 470.6 182.4 91 2.23 > 30.0 < 2 
10ix 375.4 79.9 7 1.26 > 30.0 > 1332 10xxiii 420.5 131.1 18 1.53 > 30.0 4 
10x 403.5 178.3 83 2.09 > 30.0 3 10xxiv 419.5 0.9 -2 1.00 > 30.0 1233 
10xi 409.4 186.3 24 2.96 > 30.0 3 10xxv 421.5 0.0 1 0.54 > 30.0 1227 
10xii 530.6 21.6 4 1.02 > 30.0 > 942 10xxvi 453.5 0.1 -6 1.43 > 30.0 1103 
10xiii 423.5 90.2 7 1.74 > 30.0 83 10xxvii 388.5 120.3 57 1.54 > 30.0 1287 
10xiv 400.4 172.4 31 2.4 27.6 < 3        
[a] Caco-2; Mean; PTotal (A2B) (10-7 cm/s). [b] Metabolic lability in human microsomes; Total Metabolism (%), no CYP inhibitor added. [c] LogD (pH 7.4). [d] CYP 
inhibition, IC50 (INH) (M), Isoform: CYP3A4, Substrate: Midazolam. [e] Solubility (pH 7.4; mg/ml), Mean. NoVal: Insufficient sample to perform the assay in this 
case.   
 
Interestingly, results arising from this library showed that the 
introduction of a series of amides could lead to a much broader 
range of values for both permeability and metabolic lability as 
compared to the parent tricycle system. These compounds 
showed acceptable permeability apart from 4 examples 10viii, 
10xxiv, 10xxv and 10xxvi. The proportion of compounds 
showing acceptable metabolic lability was marginally improved 
over the previous library, albeit over a much larger number of 
examples. As expected, the use of amino acid coupling partners 
resulted in compounds with the lowest metabolic lability in this 
series. As observed in the previous library, CYP inhibition was not 
a general issue with this series and only compounds 10xiv and 
10xvii providing measurable inhibition. As a conclusion, we 
identified compounds 10i, 10iv, 10v, 10ix, 10xiii and 10xv as 
having the most interesting overall physchem and eADME 
properties, albeit the latter two examples have relatively low 
solubility. 
 
Synthesis of piperazine bridged tricycles: Our synthetic strategy 
to access the 5,6,6-fused tricyclic pyrazole series involved the 
cross coupling of our common precursor 7 with 2-bromo 6-
alkoxyazine derivative, followed by hydrolysis and cyclization. 
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This synthetic route together with physchem and eADME profile 
data of this library is summarized in Table 3. 
 
Table 3. Physical and biological properties of piperazine bridged tricycles.  
 
Product Mol. Wt. Caco-2[b] Metabolic lability[c] logD[d] CYP inhibition[e] Solubility[f] 
12a 263.3 187.7 76 1.11 > 30.0 278 
12b 307.3 3.5 5 1.31 > 30.0 > 1172 
12c 280.3 173.9 58 0.54 > 30.0 26 
12d 264.3 284.2 94 0.79 > 30.0 86 
12e 282.3 NoVal 60 2.17 > 30.0 9 
12f 386.4 25.3 23 0.99 14.5 69 
[a] The coupling reaction used the corresponding arylbromide. [b] Caco-2; Mean; PTotal (A2B) (10-7 cm/s). [c] Metabolic lability in human microsomes; Total 
Metabolism (%), no CYP inhibitor added. [d] LogD (pH 7.4). [e] CYP inhibition, IC50 (INH) (M), Isoform: CYP3A4, Substrate: Midazolam. [f] Solubility (pH 7.4; 
mg/ml), Mean. NoVal: Insufficient sample to perform the assay in this case.   
 
 
Pleasingly, the coupling conditions applied earlier were also found 
to be successful in introducing the azine groups using either aryl 
bromides or chlorides. Acidic hydrolysis followed by tosylation of 
the primary alcohol promoted in situ cyclization to the desired 
tricyclic compounds 12a-f. This series exhibited generally high 
metabolic lability, with only 12b and 12f showing promising 
properties. However, the permeability of the cyclized compounds 
was encouraging and the solubility values were good to excellent. 
Overall however, as a conclusion, these 5-6-6 fused tricyclic 
compounds have less favorable overall properties as compared 
to the previous 5-7-6 fused systems, although only a limited 
selection of substitution patterns were evaluated. 
Conclusion 
We have successfully shown that pyrazole trifluoroborates are 
suitable precursors for automated parallel synthesis of novel 
tricyclic heteroaromatics. Efficient and regioselective synthesis of 
N-ethanol-pyrazole-5-trifluoroborate 1 and careful design of 
Suzuki partners enabled straightforward access to two unique 
classes of fused pyrazolotricycles with a broad range of 
physicochemical and eADME properties. The extension of this 
chemistry to the library synthesis of polycycles based on 
alternative heteroaromatic cores is underway and will be reported 
in due course. 
Experimental Section 
Potassium 2-(3-phenyl-5-(trifluoroboranyl)-1H-pyrazol-1-yl)ethan-1-
ol (7). To a solution of ynone 6 (200 mg, 0.847 mmol) in ethanol (6 mL) at 
0 °C was added 2-hydroxyethylhydrazine (186 mg, 2.03 mmol) dropwise 
under nitrogen. The reaction was followed by 19F NMR spectroscopy, and 
upon completion, the mixture was evaporated to dryness. The residue was 
redissolved in the minimum of acetone and addition of Et2O provided the 
title compound as a 92:8 mixture of regioisomers (244 mg, 98%). Removal 
of the minor isomer was achieved by trituration in acetone, and the major 
product isolated as an orange oil after removal of solvent. 1H NMR (400 
MHz, DMSO-d6): δ 7.69 (d, J = 8.0 Hz, 2H), 7.32 (t, J = 8.0 Hz, 2H), 7.19 
(t, J = 8.0 Hz, 1H), 6.29 (s, 1H), 4.67 (t, J = 6.0 Hz, 1H), 4.17 (t, J = 7.0 Hz, 
2H), 3.73 – 3.69 (m, 2H));  13C NMR (101 MHz, DMSO-d6): δ 147.9, 134.9, 
128.3, 126.2, 124.8, 105.4, 61.1, 52.6; 19F NMR (376 MHz, DMSO-d6): δ -
136.7; 11B NMR (128 MHz, DMSO-d6): δ 2.2;  FTIR: νmax 3364 (br. w), 2947 
(w), 1604 (w), 1430 (m), 1189 (s), 1139 (s); HRMS calculated for 
C11H1111BOF3N2 (ESI-): 255.0922. Found: 255.0928. 
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General Procedure for the Synthesis of oxazepane bridged tricycles 
9. In a RG24-flask, the aryl bromide partner (0.5 mmol, 1 equiv) was put 
under argon atmosphere. Na2CO3 (1.5 mmol, 3 equiv) was added, 
followed by compound 7 (0.6 mmol, 1.2 equiv) in ethanol (3 mL). 
Palladium(II) acetate (0.04 mmol, 0.07 equiv) and XPhos ligand (0.07 
mmol, 0.14 equiv) were added in ethanol (2 mL). The mixture was then 
heated at 80 °C until completion of the reaction (as judged by LC-MS 
analysis). Si-TMT-Scavenger (150 mg) was added and the reaction was 
stirred at rt for 4 h, filtered and washed with ethanol (2 mL). The crude was 
evaporated and redissolved in DMF and purified by preparative HPLC to 
yield the corresponding biaryl products. In the case of 9d, the oxazepane 
product was formed directly in this step. 
In a sealed tube, the biaryl intermediate (1 equiv) was dissolved in DMF 
(0.07 M) together with NaH (60% in paraffin; 1.1 equiv) and the mixture 
heated at 80 °C. The reaction was left to stir overnight and quenched by 
addition of water. The aqueous layer was acidified to pH 1 with HCl (37%) 
and extracted with CH2Cl2. The organic layer were dried over Na2SO4, 
filtered and all volatiles were removed. The residue was purified using 
reversed phase chromatography to yield compounds 9. 
Representative example: 2-(5-(3-fluoro-6-(trifluoromethyl)pyridin-2-
yl)-3-phenyl-1H-pyrazol-1-yl)ethanol (9f). Following the general 
procedure, 2-bromo-3-fluoro-6-(trifluoromethyl)pyridine (127 mg, 0.50 
mmol), 7 (163 mg, 0.55 mmol), Pd(OAc)2 (7 mg, 0.04 mmol), XPhos (33 
mg, 0.08 mmol) and Na2CO3 (109 mg, 1.00 mmol) were heated in ethanol 
(2.5 mL), the biaryl intermediate was obtained after reverse phase 
chromatography as a colourless oil (100 mg, 55%). 
Following the general procedure using the biaryl product from the previous 
step (69 mg, 0.20 mmol) and NaH (60% in mineral oil, 9 mg, 0.22 mmol) 
in DMF (3.5 mL), the title compound was obtained after reverse phase 
chromatography as a colourless oil (46 mg, 71%). 1H NMR (400 MHz, 
DMSO-d6): δ 7.89 (d, J = 7.0 Hz, 2H), 7.82 (d, J = 8.5 Hz, 1H), 7.74 (d, J 
= 8.5 Hz, 1H), 7.47 – 7.39 (m, 3H), 7.34 (t, J = 7.0 Hz, 1H), 4.81 – 4.79 (m, 
2H), 4.69 – 4.67 (m, 2H);  13C NMR (101 MHz, DMSO-d6): δ 154.2, 149.6, 
141.5, 140.0 (d, J = 35.0 Hz), 135.7, 132.5, 130.4 (br), 128.7, 127.8, 125.2, 
121.9 (d, J = 168.0 Hz), 120.6 (d, J = 102.5 Hz), 104.5, 68.5, 54.4; 19F 
NMR (376 MHz, DMSO-d6): δ -65.6;  FTIR: νmax 1593 (w), 1487 (m), 1455 
(m), 1441 (m), 1354 (s), 1333 (s), 1286 (s), 1223 (s), 1163 (s), 1142 (s), 
1120 (s); HRMS calculated for C17H12F3N3O (ESI+): 332.1005. Found: 
332.1011. 
Representative example: 2-Phenyl-5,6-dihydrobenzo[f]pyrazolo[1,5-
d][1,4]oxazepine-8-carboxylic acid (9i). Following the general procedure, 
3-bromo-2-fluorobenzoic acid (110 mg, 0.50 mmol), 7 (163 mg, 0.55 mmol), 
Pd(OAc)2 (8 mg, 0.04 mmol), XPhos (34 mg, 0.08 mmol) and Na2CO3 (111 
mg, 1.00 mmol) were heated in ethanol (2.5 mL), the biaryl intermediate 
was obtained after reverse phase chromatography as a colourless oil (87 
mg, 48%). 
Following the general procedure using the biaryl product from the previous 
step (396 mg, 1.21 mmol) and NaH (60% in mineral oil, 243 mg, 6.07 
mmol) in DMF (17 mL), the title compound was obtained after reverse 
phase chromatography as an off-white amorphous solid (141 mg, 38%). 
1H NMR (400 MHz, DMSO-d6): δ 8.06 (dd, J = 8.0, 1.5 Hz, 1H), 7.86 (d, J 
= 7.5 Hz, 2H), 7.57 (dd, J = 7.5, 1.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.38 
(s, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.24 (t, J = 8.0 Hz, 1H), 4.70 – 4.62 (m, 
2H), 4.62 – 4.53 (m, 2H);  13C NMR (101 MHz, DMSO-d6): δ 158.7, 156.3, 
152.0, 149.7, 140.1, 132.8, 129.0, 128.7, 127.7, 125.3, 125.0, 120.6, 115.5, 
103.1, 68.4, 54.5; FTIR: νmax 3316 (w), 3047 (w), 2961 (w), 2906 (w), 1703 
(m), 1288 (m); HRMS calculated for C18H14N2O3 (ESI+): 307.1077. Found: 
307.1081. 
General Procedure for the Synthesis of piperazine bridged tricycles 
12. In a RG24-flask, the aryl bromide partner (0.5 mmol, 1 equiv) was 
placed under argon atmosphere. Na2CO3 (1.5 mmol, 3 equiv) was added, 
followed by compound 7 (0.6 mmol, 1.2 equiv) in ethanol (3 mL). 
Palladium(II) acetate (0.04 mmol, 0.07 equiv) and XPhos ligand (0.07 
mmol, 0.14 equiv) were added in ethanol (2 mL). The mixture was then 
heated at 80 °C until completion of the reaction (as judged by LC-MS 
analysis). Si-TMT-Scavenger (150 mg) was added and the reaction was 
stirred at rt for 4 h, filtered and washed with ethanol (2 mL). The crude was 
evaporated and redissolved in DMF and purified by preparative HPLC to 
yield the corresponding biaryl products.  
A solution of HCl (4 M in 1,4-dioxane or water) was added to a solution of 
biaryl product (1 equiv) in 1,4-dioxane (0.15 M). The mixture was heated 
at reflux in a sealed tube. Upon completion, all volatiles were removed and 
the crude material was purified by column chromatography to yield the 
desired 2-pyridone product. 
Tosyl chloride (2 equiv) and cesium carbonate (6 equiv) were added to a 
solution of 2-pyridone product from the previous step (1 equiv) in DMF 
(0.04 M) and the mixture was heated at reflux. Upon completion, water 
was added and the mixture was extracted with CH2Cl2. The organic layer 
was dried over Na2SO4 and filtered. All volatiles were removed and the 
crude was purified by column chromatography to afford the desired 
compounds 12. 
Representative example: 2-Phenyl-5H-pyrazolo[1,5-a]pyrido[2,1-
c]pyrazin-8(6H)-one (12a). Following the general procedure, 2-bromo-6-
methoxypyridine (370 µL, 3.00 mmol), 7 (970 mg, 3.30 mmol), Pd(OAc)2 
(48 mg, 0.21 mmol), XPhos (207 mg, 0.42 mmol) and Na2CO3 (637 mg, 
6.00 mmol)  were heated in ethanol (15 mL), the biaryl intermediate was 
obtained after reverse phase chromatography as an orange oil (851 mg, 
96%). 
Following the general procedure, the biaryl product (204 mg, 0. 62 mmol) 
was heated HCl in 1,4-dioxane (3.1 mL), the title compound was obtained 
after reverse phase chromatography as a colourless oil (161 mg, 91%). 
Following general procedure, using the 2-pyridone from the previous step 
(145 mg, 0.52 mmol), tosyl chloride (204 mg, 1.03 mmol) and cesium 
carbonate (1.02 g, 3.09 mmol) in DMF (14 mL), the title compound was 
obtained after reverse phase chromatography as a colourless oil (116 mg, 
85%). 1H NMR (400 MHz, DMSO-d6): δ 7.84 (dd, J = 8.0, 1.0 Hz, 2H), 7.54 
(dd, J = 9.0, 7.0 Hz, 1H), 7.48 – 7.40 (m, 3H), 7.34 (t, J = 7.0 Hz, 1H), 6.79 
(dd, J = 7.0, 1.0 Hz, 1H), 6.46 (dd, J = 9.0, 1.0 Hz, 1H), 4.55 – 4.47 (m, 
2H), 4.47 – 4.41 (m, 2H); 13C NMR (101 MHz, DMSO-d6): δ 160.6, 150.9, 
139.5, 135.3, 134.3, 132.5, 128.8, 128.0, 125.1, 118.7, 102.7, 100.8, 45.1, 
39.7; FTIR: νmax 3111 (w), 3065 (w), 2923 (w), 1653 (s), 1575 (s), 1529 (s), 
1514 (m), 1458 (m), 1143 (s); HRMS calculated for C16H13N3O (ESI+): 
264.1131. Found: 264.1134. 
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